Therapeutic Effects Of Apatinib Mesylate On Non-Small Cell Lung Cancer And Cellular Immune Function

This study was designed to investigate the clinical effects of apatinib mesylate in chemotherapy of patients with non-small cell lung cancer (NSCLC) and its effect on cellular immune function. A total 300 patients with NSCLC were randomly divided into control group and observation group (n = 150 each group). The control group was treated with paclitaxel monotherapy while the observation group was treated with apatinib mesylate. Both groups were treated for one course continuously. The clinical efficacy was evaluated after treatment. The serum levels of CEA, CYFRA21-1, VEGF and MMP-9 were measured by enzyme-linked immunosorbent assay pre and post treatment. T lymphocyte subsets CD4+, CD8+, and CD4+/CD8+ ratio were measured by flow cytometry before and after treatment. In addition, the incidence of toxic and side effects during the treatment of the two groups were counted, and the clinical efficacy and the influence on the cellular immune function of the two groups were compared. The levels of CEA, CYFRA21-1, VEGF and MMP-9 in the two groups after 1 month of treatment were statistically lower (p < 0.05) than before treatment, and the levels of CEA, CYFRA21-1, VEGF and MMP-9 in the observation group after 1 month of treatment were lower than the control group. In addition, the CD4+, CD8+, and CD4+/CD8+ ratio of T lymphocyte subsets in the observation group after 1 month of treatment were higher than control group. Finally, the incidence of nausea and vomiting, diarrhea, neurotoxicity, bone marrow suppression, hepatotoxicity and nephrotoxicity in the observation group after 1 month of treatment were lower than control group. Apatinib mesylate is effective in the treatment of NSCLC, which is helpful to improve the level of tumor markers, has little effect on cellular immune function, and has high drug safety, so it is worthy of popularization and application.